Every material Form 8-K ENDRA Life Sciences Inc. has filed with the SEC since July 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ENDRA Life Sciences amended its June 25, 2026 merger agreement with ASP Isotopes and related parties on October 1, 2026, removing the classified board requirement, revising the minimum cash closing condition to $3,800,002.59 less agreed expenses, and allowing ASP-related lending to Renergen to rise from $80 million to up to $200 million. The company also amended warrants held by an ASP Isotopes affiliate to remove the 4.99% beneficial ownership limit, which changes how that affiliate can exercise them.
Amendment dated October 1, 2026 changes the merger terms, including the minimum cash closing condition of $3,800,002.59, less agreed expenses.
Renergen's ASPI borrowing capacity would rise from $80 million to up to $120 million, then to up to $200 million at or before closing.
Warrant amendments remove the 4.99% beneficial ownership limitation for LHE LNG Holdings, an ASP Isotopes subsidiary.
Warrants covering 324,372 pre-funded shares and all common warrants become exercisable only after stockholder approval.
ENDRA reported net income of $159,944 for the quarter ended June 30, 2026, compared with a net loss of $1,225,912 a year earlier. The result came from $1.6 million in other income, mainly digital asset gains, while total operating expenses rose to $1.5 million from $1.3 million. The company is pursuing a merger with Noble Africa LLC, which is expected to close in the fourth quarter of 2026 and would rename ENDRA Noble Africa Inc.
Q2 2026 net income was $159,944, versus a net loss of $1,225,912 in Q2 2025.
Total operating expenses were $1,483,256, up from $1,301,090; other income was $1.6 million, mainly from digital asset gains.
As of June 30, 2026, cash was $1,739,943 and restricted cash was $3,800,003.
Merger agreement with Noble Africa dated June 25, 2026; closing expected in Q4 2026, subject to stockholder and regulatory approvals.
ENDRA Life Sciences received a Nasdaq notice on July 8, 2026 that it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, after the Staff flagged a shortfall in its 2025 annual report. The company will be under a Discretionary Panel Monitor for one year from July 1, 2026, and if it falls out of compliance again within that period, it could face delisting without a cure period.
Nasdaq Staff letter dated April 20, 2026 cited stockholders' equity below the $2,500,000 minimum, based on the 2025 Form 10-K
Company requested a Nasdaq Hearing Panel hearing on April 27, 2026; hearing held May 28, 2026
On July 8, 2026 Nasdaq notified the company it regained compliance
One-year Discretionary Panel Monitor runs from July 1, 2026; a new deficiency could lead to a Delist Determination Letter and possible delisting
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ENDRA Life Sciences Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →